HealthEquity saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 94 the day before.
Discover The 3 Keys To Successful Stock Investing
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
HealthEquity is currently forming a cup without handle, with a 115.59 buy point. See if the stock can break out in volume at least 40% higher than normal.
The stock earns an 86 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 86% of all stocks.
Its Accumulation/Distribution Rating of A- shows heavy buying by institutional investors over the last 13 weeks.
In Q4, the company reported 10% EPS growth. Top line growth fell to 19%, down from 21% in the previous quarter. The company's next quarterly report is expected on or around Jun. 3.
HealthEquity earns the No. 2 rank among its peers in the Commercial Services-Outsourcing industry group. Red Violet is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
